Inhibitory Effect of Flavonoids on the Efflux of N-Acetyl 5-Aminosalicylic Acid Intracellularly Formed in Caco-2 Cells by Shin, Yoshimura et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2009, Article ID 467489, 8 pages
doi:10.1155/2009/467489
Research Article
Inhibitory Effectof Flavonoids on the Efﬂuxof N-Acetyl
5-AminosalicylicAcidIntracellularlyFormedinCaco-2 Cells
ShinYoshimura,KentaroKawano,RyusukeMatsumura,NarumiSugihara,andKojiFuruno
Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Sanzou, Gakuen-cho, Fukuyama,
Hiroshima 729-0292, Japan
Correspondence should be addressed to Koji Furuno, furuno@fupharm.fukuyama-u.ac.jp
Received 7 February 2009; Revised 13 May 2009; Accepted 1 June 2009
Recommended by Mostafa Z. Badr
N-acetyl 5-aminosalicylic acid (5-AcASA) that was intracellularly formed from 5-aminosalicylic acid (5-ASA) at 200μMw a s
discharged 5.3, 7.1, and 8.1-fold higher into the apical site than into the basolateral site during 1, 2, and 4-hour incubations,
respectively, in Caco-2 cells grown in Transwells. The addition of ﬂavonols (100μM) such as ﬁsetin and quercetin with 5-ASA
remarkably decreased the apically directed eﬄux of 5-AcASA. When 5-ASA (200μM) was added to Caco-2 cells grown in tissue
culture dishes, the formation of 5-AcASA decreased, and, in addition, the formed 5-AcASA was found to be accumulated within
the cells in the presence of such ﬂavonols. Thus, the decrease in 5-AcASA eﬄux by such ﬂavonols was attributed not only to
the inhibition of N-acetyl-conjugation of 5-ASA but to the predominant cellular accumulation of 5-AcASA. Various ﬂavonoids
also had both of the eﬀects with potencies that depend on their speciﬁc structures. The essential structure of ﬂavonoids was an
absence of a hydroxyl substitution at the C5 position on the A-ring of ﬂavone structure for the inhibitory eﬀect on the N-acetyl-
conjugation of 5-ASA, and a presence of hydroxyl substitutions at the C3  or C4  position on the B-ring of ﬂavone structure for the
promotingeﬀectonthecellularaccumulationof5-AcASA.Boththedecreasein5-AcASAapicaleﬄuxandtheincreasein5-AcASA
cellular accumulation were also caused by MK571 and indomethacin, inhibitors of MRPs, but not by quinidine, cyclosporin A,
P-glycoprotein inhibitors, and mitoxantrone, a BCRP substrate. These results suggest that certain ﬂavonoids suppress the apical
eﬄux of 5-AcASA possibly by inhibiting MRPs pumps located on apical membranes in Caco-2 cells.
Copyright © 2009 Shin Yoshimura et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Sulfasalazine used in the therapy of inﬂammatory bowel
diseases, such as ulcerative colitis and Crohn’s disease [1, 2].
Ingested sulfasalazine passes to the colon without being
absorbed in intestine and is split into 5-aminosalicylic acid
(5-ASA) and sulfapyridine by colonic bacteria [1, 2]. Most of
5-ASA is metabolized by N-acetyl-conjugation in the form
of N-acetyl 5-aminosalicylic acid (5-AcASA) in the colonic
epithelia, while sulfapyridine is quickly absorbed from the
colon and metabolized in the liver [3–5]. It has been pro-
posed that 5-ASA, the active moiety of sulfasalazine, exerts
an antiinﬂammatory activity by inhibiting prostaglandin
synthesis in colonic mucosa [6, 7] .S o m er e p o r t sh a v es h o w n
that 5-AcASA has a potency as an inhibitor of prostaglandin
synthesis comparable to that of 5-ASA [7], and therapeu-
tically active when administered by enema to patients with
ulcerative colitis [8]. However, 5-AcASA formed in colonic
epithelia is immediately secreted into mucosal lumen and
excreted in feces [9–11]. Thus, 5-AcASA is considered the
portion that has already exerted therapeutical action within
the bowel tissue [1–3, 9–11]. Zhou et al. reported that
5-AcASA was exclusively transported from the basolateral
to the apical direction using human colon-derived Caco-2
cells [11]. However, the mechanism underlying the cellular
transport of 5-AcASA has not extensively elucidated. It
is well known that ﬂavonoids (Figure 1), plant-derived
compounds, alter the function of eﬄux transporters such as
P-glycoprotein, that is, present in epithelium cells [12–14].
Recently, several researchers reported the inhibitory inter-
action of ﬂavonoids with multidrug resistance-associated
proteins (MRPs) that are responsible for active secretion of2 Journal of Biomedicine and Biotechnology
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Figure 1: Structure of ﬂavonoids.
pharmacologically relevant drugs [15–20]. In this study, the
eﬀect of ﬂavonoids and transporter inhibitors on the cellular
eﬄux of 5-AcASA that was intracellularly formed from 5-
ASA was examined in Caco-2 cells. Certain ﬂavonoids and
MRPs inhibitors displayed strong potency in decreasing the
preferential apical eﬄux of 5-AcASA and in increasing the
cellular accumulation of 5-AcASA in Caco-2 cells.
2.MaterialsandMethods
2.1. Materials. Materials and chemical reagents were pur-
chased from the following companies: Transwells from
CorningCostar(Cambridge,MA,USA);tissueculturedishes
from Becton Dickinson Com. (Falcon; USA); ﬂavonoids
from Funakoshi Co. (Tokyo, Japan); 5-ASA and quinidine
from Sigma-Aldrich Com. (Japan); MK571 from Alexis
Biochemicals (Lausen, Switzerland); mitoxantrone from
LKT Laboratories (MA, USA); indomethacin and other
chemicals used from Wako Pure Chemical Co. (Osaka,
Japan); and the Develosil RPAQUEOUS C-30-UG-3 column
(4.6I.D. × 150mm) from Nomura Chemical Co. (Aichi,
Japan). Cyclosporin A was purchased from Sigma-Aldrich
Com. and Wako Pure Chemical Co. 5-AcASA was synthe-
sized by the reaction of 5-ASA with acetic anhydride, as
described by other researchers [21].
2.2. Eﬄux of 5-AcASA from Caco-2 Cells. Caco-2 cells
were purchased from the Riken (no. RCB0988) and used
as previously described [22]. The cell line was cultured
in Dulbecco’s modiﬁed Eagle’s medium containing 12%
fetalcalfserumandpenicillin-streptomycin-amphotericinB.
The suspended cells were seeded on 6-well- polycarbonate
Transwell inserts (0.4μm mean pore size, 4.7cm2 growth
area) at a density of 5 × 104 cells/dish, and then placed
in an incubator in an atmosphere of 5% CO2–95% air at
37◦C. The Caco-2 cells in the Transwell were grown for 3
weeks in Dulbecco’s modiﬁed Eagle’s medium containing
fetal calf serum. The monolayers with transepithelial electric
resistance of more than 250Ωcm2 were used for transport
studies. 5-ASA in a stock solution at 50mM was added to the
apical chamber at a ﬁnal concentration of 200μMa f t e r1 0
minutes of the addition of ﬂavonols. After incubation for 2
a n d4h o u r sa t3 7 ◦C, 50μL of the medium from both of the
chambers was mixed with 50μLo f0 . 5Mp e r c h l o r i ca c i d .Journal of Biomedicine and Biotechnology 3
Table 1: The eﬀect of ﬂavonols and transporter inhibitors on the apical and basolateral eﬄux of N-acetyl 5-aminosalicylic acid in Caco-2
cells. Caco-2 cells grown in Transwells were incubated with 200μM 5-ASA for 1, 2, and 4 hours in the presence of ﬂavonols and transporter
inhibitors at the concentration of 100μM. Api: apical eﬄux of 5-AcASA, Baso: basolateral eﬄux of 5-AcASA. Each value represents the mean
± SD of four to ﬁve experiments.
Control Fisetin Quercetin Morin MK571 Quinidine
1hr
Api (nmol) 1.01 ±0.14 0.16 ±0.06∗∗ 0.32 ±0.07∗∗ 0.87 ±0.03 0.47 ±0.13∗∗ 0.91 ± 0.16
Baso (nmol) 0.19 ±0.02 0.31 ±0.09∗∗ 0.47 ±0.08∗∗ 0.43 ±0.01∗∗ 0.45 ±0.04∗∗ 0.18 ± 0.03
Api/Baso 5.32 ±0.38 0.52 ±0.11∗∗ 0.68 ±0.06∗∗ 2.02 ±0.04∗∗ 1.04 ±0.19∗∗ 5.06 ± 0.21
2hr
Api (nmol) 2.05 ±0.28 0.36 ±0.13∗∗ 0.80 ±0.21∗∗ 1.64 ±0.15 1.05 ±0.05∗∗ 1.96 ± 0.59
Baso (nmol) 0.29 ±0.04 0.47 ±0.11∗∗ 0.94 ±0.07∗∗ 0.66 ±0.06∗∗ 0.70 ±0.03∗∗ 0.28 ± 0.07
Api/Baso 7.07 ±0.19 0.77 ±0.16∗∗ 0.85 ±0.16∗∗ 2.48 ±0.04∗∗ 1.50 ±0.11∗∗ 7.00 ± 0.18
4hr
Api (nmol) 5.04 ±0.61 0.89 ±0.25∗∗ 2.16 ±0.35∗∗ 3.62 ±0.94 2.30 ±0.22∗∗ 4.61 ± 0.72
Baso (nmol) 0.62 ±0.08 0.97 ±0.21∗∗ 2.05 ±0.17∗∗ 1.15 ±0.20∗ 1.14 ±0.09∗∗ 0.59 ± 0.10
Api/Baso 8.13 ±0.27 0.92 ±0.16∗∗ 1.05 ±0.23∗∗ 3.15 ±0.10∗∗ 2.02 ±0.11∗∗ 7.81 ± 0.06
Signiﬁcant diﬀerence from control ∗P<. 05, ∗∗P<. 01.
2.3. Cellular Accumulation of 5-AcASA. Caco-2 cell line at
passage of 40 was used for the experiments. The suspended
cells in Dulbecco’s modiﬁed Eagle’s medium containing 12%
fetal calf serum and penicillin-streptomycin-amphotericin B
were seeded on 35mm plastic culture dishes at a density
of 5 × 104 cells/dish. After seeding, the cells were cultured
in a 37◦C incubator under 5% CO2–95% air at 37◦C
for two weeks until the cells were fully diﬀerentiated into
conﬂuent enterocyte-like monolayers. Flavonoids, 5-ASA
andotherchemicalsweredissolvedindimethylsulfoxideand
added to the medium at deﬁnite concentrations, with the
ﬁnal concentration of dimethyl sulfoxide about 1%. After
incubation for 2 hours, the cell monolayers were washed
twice with Hanks balanced solution and harvested. The
adequate volume of the medium and cell suspensions was
treated with the same volume of 0.5M perchloric acid.
2.4. HPLC Analysis. Chromatographic separation and quan-
titative determination were carried out according to the
HPLC analytical methods described previously [23]. A
0.1mLaliquotofperchloricacid-treatedsamplewasneutral-
ized with 25μL of 1M NaOH solution and 25μLo f0 . 5M
Tris-HCl buﬀer (pH 7.4), and the total volume was adjusted
to 0.5mL with HPLC elution solvent. A 50μLa l i q u o to f
sample was injected onto a Develosil C-30-UG-3 (4.6I.D.
× 150mm) column adjusted to 40◦C, and 5-AcASA was
separated by solution with a mixture of acetonitrile (4%)
and 20mM phosphate buﬀer (pH 5.0 solution) using a
CCPD HPLC system equipped with an FS-8020 ﬂuorescence
detector (Tosoh Co., Japan). The ﬂow rate of the mobile
phase was 1.0mL/min, and elution of 5-ASA and 5-AcASA
was monitored at a ﬂuorescence excitation wavelength of
310nm and an emission wavelength of 480nm. 5-ASA and
5-AcASA were eluted at 2.7 and 11.5 minutes, respectively.
The quantitative determination of 5-AcASA was based upon
the integration of ﬂuorescence peak areas.
2.5. Statistical Analysis. The data in ﬁgures are given as the
mean ± S.D. of four to ﬁve experiments. Diﬀerences among
the mean values were assessed by Dunnett’s test using Stat-
100 (BIOSOFT, UK) or Student’s t-test. A P value of < 0.05
was considered signiﬁcant.
3. Results
The incubation of Caco-2 cells with 5-ASA formed only
one peak of 5-ASA metabolite, which was identiﬁed as
5-AcASA by the same retention time as the synthesized
standard in HPLC. The N-acetyl-conjugative reaction of 5-
ASAinCaco-2cellswassaturatedabove1mMof5-ASA.The
eﬀect of ﬂavonols and inhibitors of transporters on 5-AcASA
eﬄux was examined using Caco-2 cell monolayers grown
in Transwells which contained 1.5 and 2.6mL Dulbecco’s
modiﬁed Eagle’s medium in the apical and basolateral
chambers, respectively. 5-ASA was loaded at 200μMi n
the apical chamber and 5-AcASA discharged from both of
the apical and basolateral sites was measured. After 1, 2,
and 4-hour incubation, amounts of 5-AcASA were 1.01,
2.05, and 5.04nmoles in the apical chamber and 0.19, 0.29,
and 0.62nmoles in the basolateral chamber, respectively
(Table 1). The apical eﬄux of 5-AcASA was 5.32, 7.07, and
8.13-fold higher than the basolateral eﬄux at 1, 2, and 4-
hour incubation, respectively. When ﬁsetin and quercetin
(100μM) were added with 5-ASA to Caco-2 cells, the
apicaleﬄuxof5-AcASAdecreasedremarkably(Table 1).The
basolateraleﬄuxof5-AcASAratherincreasedinthepresence
of such ﬂavonols. The ratios for the apical to the basolateral
eﬄux of 5-AcASA actually decreased to 0.52 and 0.68 at 1
hour, 0.77 and 0.85 at 2 hours, and 0.92 and 1.05 at 4-
hour incubation, in the presence of ﬁsetin and quercetin,
respectively. Morin had a weaker eﬀect than ﬁsetin and
quercetin. MK571, a MRPs inhibitor, showed a similar eﬀect
to quercetin; however, quinidine, a P-glycoprotein inhibitor,
had no eﬀects.
Figure 2 shows the time course of the amount of 5-
AcASA in the cells, medium, and their total (cells plus
medium), and the percentage of cellular accumulation of
5-AcASA at 1, 2, and 4-hour incubation in the presence
of ﬂavonols (100μM) with 5-ASA (200μM) in Caco-2 cells4 Journal of Biomedicine and Biotechnology
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Figure 2: (a) The time course curve of N-acetyl 5-aminosalicylic acid in Caco-2 cells, (b) the medium and (c) the total, and (d) the cellular
accumulation percent. Caco-2 cells grown in tissue culture dishes were incubated with 200μM 5-ASA for 1, 2, and 4 hours in the absence ( )
and the presence of quercetin ( ), ﬁsetin ( ), and morin ( ) at the concentration of 100μM. Cell 5-AcASA (%): (cells/cells plus medium) ×
100. Each point represents the mean ± SD of four to ﬁve experiments. Signiﬁcant diﬀerence from control ∗P<. 05, ∗∗P<. 01.
grown in tissue culture dishes. 5-AcASA was formed at
the rate of 4nmol/h/1 × 106 cells during a 4 h-incubation
period in the control cells. Flavonoids are potent inhibitors
of N-acetyltransferase [23]. Fisetin remarkably decreased
the formation of 5-AcASA from 5-ASA in Caco-2 cells.
Furthermore, a large amount of 5-AcASA was found in
the cells treated by quercetin. The amount of 5-AcASA
inside the control cells was 12 percent of the total 5-
AcASA at a 1 h-incubation and decreased to 6.3 and
3.2 percents at 2 and 4-hour incubation, respectively. The
cellular accumulation rate increased by several-fold than
that of the control cells by quercetin and ﬁsetin, and
increased slightly by morin during a 4 h-incubation period.
Figure 3 shows the amount of 5-AcASA in the cells and
medium in the presence of various ﬂavonoids at a 2 h-
incubation. Flavonoids that lack a hydroxyl substitution
at the C5 position on the A-ring had a strong inhibitory
eﬀect on the N-acetyl-conjugation of 5-ASA. The total 5-
AcASA formed in the presence of ﬁsetin, 7,3 ,4 -OH ﬂavone,
7,4 -OH ﬂavone and geraldol decreased to 16.3, 23.3, 54.3,
and 68.3 percents of that of the control cells, respectively.
Furthermore, most of ﬂavonols and ﬂavones caused an
abundant cellular accumulation of 5-AcASA inside the cells.
The cellular 5-AcASA accumulation was 52.7 percent of
the total formed in the presence of quercetin, the most
eﬀective one among ﬂavonoids tested (Table 2). Flavonoids
that lack a C2-3 double bond or a carboxyl group at the
C4 position on the C-ring, such as catechins and taxifolin,
had no eﬀects. The structural feature required for the
potent eﬀect on the cellular 5-AcASA accumulation was
a presence of hydroxyl group on the B-ring of ﬂavone
structure.The eﬀect of inhibitors or substrate of transporters
on the cellular 5-AcASA accumulation was compared with
ﬂavonols at a 2 h-incubation with 200μMo f5 - A S Ai n
Caco-2 cells (Figure 4). MK-571 and indomethacin, MRPs
inhibitors [24–26], increased in concentration-dependent
manner the cellular 5-AcASA accumulation, while they did
not aﬀect the formation of 5-AcASA. MK-571 was more
eﬀective than indomethacin and showed equivalent eﬃcacy
to quercetin and ﬁsetin. On the other hand, qunidine, aJournal of Biomedicine and Biotechnology 5
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Figure 3: The amount of N-acetyl 5-aminosalicylic acid in Caco-2
cells and the medium. Caco-2 cells grown in tissue culture dishes
were incubated with 200μM5 - A S Af o r2h o u r si nt h ep r e s e n c eo f
ﬂavonoids at the concentration of 100μM. 5-ASA in cells (Closed
column), 5-ASA in medium (Open column). Each bar represents
the mean ± SD of four to ﬁve experiments. Signiﬁcant diﬀerence
from control ∗P<. 05, ∗∗P<. 01.
P-glycoprotein inhibitor, and cyclosporine A, an inhibitor
of both P-glycoprotein and MRPs [27, 28], did not aﬀect
the cellular 5-AcASA accumulation. Mitoxantrone, a breast
cancer resistance protein (BCRP) substrate [29], had no
eﬀectseitherattheconcentrationof20μM(datanotshown).
4. Discussion
5-AcASA that was formed from 5-ASA in the interior of
cells was discharged preferentially to the apical direction
compared to the basolateral direction in Caco-2 cells grown
in Transwells. Quercetin and ﬁsetin remarkably decreased
the apical eﬄux of 5-AcASA, while morin did with a less
potency. The amount of 5-AcASA in Caco-2 cells and the
medium was measured during a 4 h-incubation with 5-ASA
in the presence of such ﬂavonols. Flavonoids are eﬀective
inhibitors of N-acetyl-conjugation of 5-ASA in rat liver
cytosol preparation [23]. Fisetin, in particular, exhibited
strong inhibitory activity on 5-AcASA formation in Caco-
2 cells. Thus, the inhibition of 5-AcASA formation is likely
to contribute largely to the decrease in the 5-AcASA eﬄux
in the case of ﬁsetin. However, quercetin showed a much
weaker inhibitory eﬀect on the 5-AcASA formation than
ﬁsetin. Surprisingly, the formed 5-AcASA was found to
be accumulated inside the cells treated by ﬂavonols. For
quercetin, the cellular accumulation of 5-AcASA coincides
with the decrease in 5-AcASA apical eﬄux. An increase
in the basolateral eﬄux of 5-AcASA during an incubation
of Transwells is probably due to the extensive cellular
accumulation of 5-AcASA particularly in quercetin-treated
cells.
A large group of ﬂavonoids were examined for their
inhibitory eﬀects on the 5-AcASA formation as well as their
promoting eﬀects on the cellular 5-AcASA accumulation. A
key chemical determinant necessary for exerting the strong
inhibitory eﬀect on the N-acetyl-conjugation of 5-ASA was a
lackof hydroxyl substitution atthe C5 position on the A-ring
ofﬂavonestructuresuchasﬁsetinand7,3 ,4 -OHfavone.On
theotherhand,thestructuralrequirementforthepromoting
eﬀect on cellular 5-AcASA accumulation was a presence of
hydroxyl substitution at the C3  or C4  position on the B-
ring of ﬂavone structure. Therefore, the inhibition of 5-
AcASA formation and the promotion of cellular 5-AcASA
accumulation by ﬂavonoids seem to be caused by diﬀerent
mechanisms.
The results mentioned above suggest that 5-AcASA is
pumped out by an active eﬄux transporter located on the
apical membrane and certain ﬂavonoids appear to play an
important replacing role in the apical-directed transport of
5-AcASA in Caco-2 cells. Flavonoids are well-known modu-
latorsofthecellulartransportofvarioussubstancesmediated
by P-glycoprotein which is localized on apical membranes in
polarizedcells[12–14].Recently,severalresearchersreported
the interaction of ﬂavonoids with MRPs transporters. Wal-
gren et al. reported that the eﬄux of quercetin 4 -beta-
glucoside across Caco-2 cell monolayers was mediated by
MRP2[24].VanZandenetal.studiedontheinhibitoryeﬀect
of quercetin on MRPs pump-mediated eﬄux of calcein and
vincristine, well-known MRPs substrates, in the MRP1 and
MRP2 transfected MDCK cells [18–20]. They mentioned
that MRP2 displayed higher selectivity for ﬂavonoid-type
inhibitionthanMRP1.PhaseIImetabolitesofvariousdrugs
conjugated to glutathione, glucuronate, or sulfate are gener-
ally considered to be transported by MRPs-like transporters
[30–32]. MRPs were characterized as the canalicular multi-
speciﬁc organic anion transporters that function in terminal
secretion into bile canaliculus of endo- and xenobiotics such
as acetaminophen metabolites, bilirubin glucuronides, 2,4-
dinitrophoenyl-S-glutathione, 17β-glucuronosyl estradiol,
and 4-methylumbelliferyl glucuronide that are conjugated in
hepatocytes [33–35]. The transcellular transport of acetyl-
conjugated 5-ASA from the basolateral site to the apical
site in Caco-2 cell was ﬁrst reported by Zhou et al. [11].
However, the transporter-mediated eﬄux of 5-AcASA has
not been investigated thoroughly. To address the interest
in involvement of transporters that are responsible for the
5-AcASA apical eﬄux in Caco-2 cells, several inhibitors
of transporters were examined for their suppressing eﬀect
on the 5-AcASA apical eﬄux and promoting eﬀect on the
cellular 5-AcASA accumulation. MK571 and indomethacin,
inhibitors of MRPs had similar eﬀects to ﬂavonoids. Quini-
dine, a P-glycoprotein inhibitor, and Cyclosporine A, an
inhibitor of P-glycoprotein and MRPs [27, 28], showed
no eﬀects. Absence of inhibitory activity of Cyclosporine
A may be explained by substrate speciﬁcity of 5-AcASA
for MRPs. Mitoxantrone, a substrate of BCRP [29], had
no eﬀects either. These results suggest that 5-AcASA is
possibly pumped out by an MRPs-like transporter and
certain ﬂavonoids inhibit their eﬄux-pump activity in Caco-
2 cells.
Flavonoids are part of the human diet and possess
many health beneﬁts with low toxicity [36, 37]. However,
ﬂavonoids are poorly absorbable compounds from the6 Journal of Biomedicine and Biotechnology
Table 2: The cellular accumulation percent of in N-acetyl 5-aminosalicylic acid Caco-2 cells. Caco-2 cells grown in tissue culture dishes
were incubated with 200μM 5-ASA for 2 hours in the presence of ﬂavonoids at the concentration of 100μM. Cellular accumulation percent:
(cells/cells plus medium) × 100. Each value represents the mean ± SD of four to ﬁve experiments.
Flavonoids Cellular accumulation (%) Flavonoids Cellular accumulation (%)
Control 5.5 ± 0.87 , 3  ,4 -O Hﬂ a v o n e 3 8 .7 ±4.2∗∗
Epicatechin 5.7 ± 0.3 Diosmetin 41.8 ±2.4∗∗
Epigallocatechin 5.8 ± 0.3 Fisetin 42.7 ±1.2∗∗
Taxifolin 6.9 ± 0.67 , 4  -OH ﬂavone 42.8 ±4.5∗∗
5-OH ﬂavone 9.2 ±0.2∗∗ Kaempferol 43.1 ±0.7∗∗
Morin 9.9 ±0.3∗∗ Isorhamnetin 45.4 ±4.1∗∗
3-OH ﬂavone 17.4 ±0.9∗∗ Apigenin 45.7 ±2.3∗∗
7-OH ﬂavone 20.1 ±3.8∗∗ Geraldol 50.2 ±1.1∗∗
Galangin 21.3 ±3.1∗∗ Luteolin 50.7 ±3.2∗∗
Chrysin 31.7 ±3.5∗∗ Quercetin 52.7 ±2.5∗∗
3 ,4 -OH ﬂavones 36.7 ±3.6∗∗
Signiﬁcant diﬀerences from control ∗P < .05, ∗∗P < .01.
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Figure 4: The eﬀect of ﬂavonols and transpoter inhibitors on the cellular accumulation of N-acetyl 5-aminosalicylic acid in Caco-2 cells.
Caco-2 cells grown in tissue culture dishes were incubated with 200μM 5-ASA for 2 hours in the presence of ﬂavonols and transporter
inhibitors at the concentration of 100μM. Cellular accumulation percent : (cells/cells plus medium) × 100. Each bar represents the mean ±
SD of four to ﬁve experiments. Signiﬁcant diﬀerence from control ∗P<. 05, ∗∗P<. 01.
digestive tract in vertebrates [38, 39]. When quercetin was
given p.o. to the rats (630mg/kg), approximately 20% of
the total dose was absorbed from the digestive tract, more
than 30% was decomposed in the intestinal microﬂora,
and approximately 30% was excreted unchanged in the
feces during 72 hours [38]. After a single oral dose of
quercetin in humans (4g), approximately 53% of the
dose was recovered unchanged in the feces. Thus it was
concluded that 1% of the original 4g dose of quercetin
was absorbed [39]. In this study, ﬂavonoids were added at
the concentration range from 20 to 100μM only into the
apical compartment of Caco-2 cells in Transwells that faces
to intestinal lumen in vivo. A high luminal level around
100μM of ﬂavonoids is expected to be achieved with a single
oral administration of a few hundred mg of ﬂavonoids in
humans.Journal of Biomedicine and Biotechnology 7
5-ASA, an active moiety of sulfasalazine, is immediately
secreted into the luminal side from intestinal epithelia
following extensive N-acetyl-conjugation, and is ﬁnally
excreted into feces [3–5]. Zhou et al. [11] reported that
a tl u m i n a ll e v e l sb e l o w2 0 0 μg/mL (concentrations that
are typically achieved by controlled release dosage forms),
intestinal secretion of 5-AcASA accounts for more than
50% of the total 5-ASA elimination. Thus, 5-AcASA has
been considered to be therapeutically nonactive portion
[1–3, 9–11]. However, 5-AcASA has still antiinﬂammatory
potential if the drug retains within the intestinal tissues
[8]. The eﬃcacy of 5-ASA therapy correlates with tissue
delivery of 5-ASA, that is, determined by N-acetylation and
cellular discharge. The present study showed that certain
ﬂavonoidshavetheinhibitoryeﬀectonN-acetyl-conjugation
of 5-ASA and the suppressive eﬀect on the 5-AcASA apical
eﬄux in Caco-2 cells. Viewed in this light, both of these
eﬀects of ﬂavonoids seem to be desirable in the treatment
of inﬂammatory bowel diseases, since coadministration of
ﬂavonoidswith5-ASAisexpectedtoincreasethetissuelevels
of 5-ASA and 5-AcASA in intestine.
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